Colospan, a wholly owned subsidiary of Eocene, has signed its first European commercial distribution agreement with Hospital Line for its CG-100 intraluminal bypass device.
Hospital Line has secured exclusive rights for marketing, selling and distributing the device in Cyprus and Greece.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The contract includes exclusivity terms alongside agreed commercial targets, serving as a base for potential European expansion.
The upcoming commercial roll out is set to run alongside Colospan’s pivotal study of the CG-100 in the US. Further products may be added to the agreement once commercially ready.
Hospital Line is a medical device and speciality pharmaceutical distributor in Cyprus and Greece and has partnerships with companies such as LeMaitre Vascular, Boston Scientific and Panther Healthcare.
Eocene president and CEO Allen Baharaff said: “CG-100 was developed to address one of the greatest challenges in colorectal surgery by providing a potential alternative to diverting stomas.
“We look forward to introducing CG-100 together with Hospital Line and to supporting clinicians in a new approach that we believe could reduce the need for stomas for colorectal cancer patients.”
CG-100 acts as an intraluminal bypass to safeguard colorectal anastomoses. It holds CE mark certification under European Union regulations and breakthrough device designation from the US Food and Drug Administration (FDA).
While approved for US investigational use under an investigational device exemption, the device is not cleared for commercial sale in the country.
Colospan founder and CEO Boaz Assaf said: “We are very pleased to partner with Hospital Line, an established medical device distributor with strong relationships across the surgical communities in Greece and Cyprus.
“This agreement marks an important step in our European commercialisation strategy, and we believe Hospital Line is well positioned to support the adoption of CG-100 in these markets.”
Eocene, formerly known as Galmed Pharmaceuticals, is based in Ramat Gan, Israel. Its pipeline also includes Aramchol, a synthetic conjugate molecule under evaluation for gastrointestinal cancers and liver disease.
